Difluoropene

Structural formula
General
Non-proprietary name	Difluoropene
other names	(1 S , 2 S , 3 S , 5 R ) -3- [bis (4-fluorophenyl) methoxy] -8-methyl-8-azabicyclo [3.2.1] octane-2-carboxylic acid methyl ester
Molecular formula	C 23 H 25 F 2 NO 3
External identifiers / databases
PubChem	190851
Wikidata	Q1224566
Drug information
Drug class	stimulant
properties
Molar mass	401.45 g · mol -1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Difluoropin (also: O-620 ) is a stimulant that is chemically and structurally derived from the tropane alkaloids . It is synthesized from tropinone , which acts as a selective dopamine reuptake inhibitor. Also difluoropine is a dopamine reuptake inhibitor, and not the ( R ) - enantiomer is responsible for the effect, as in cocaine is the case, but the ( S ) enantiomer. It is structurally related to benzatropine and, like these, also has an anticholinergic and antihistaminic effect .

It could be shown that difluoropine has a stimulating effect in animals, but less strongly than other phenyltropanes , such as WIN 35,428 or RTI-55. Difluoropin has been shown to reduce symptoms of Parkinson's disease in animals .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ PC Meltzer, AY Liang, BK Madras: The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. In: Journal of medicinal chemistry. Volume 37, Number 13, June 1994, pp. 2001-2010, PMID 8027983 .
↑ VC Campbell, TA Kopajtic, AH Newman, JL Katz: Assessment of the influence of histaminergic actions on cocaine-like effects of 3α-diphenylmethoxytropane analogs. In: The Journal of pharmacology and experimental therapeutics. Volume 315, Number 2, November 2005, pp. 631-640, doi : 10.1124 / jpet.105.090829 , PMID 16055673 .
↑ Katz, JL; Izenwasser, S .; Kline, RH; Allen, AC; Newman, AH: Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. In: Journal of Pharmacology and Experimental Therapeutics (Jan. 1999; 288 (1)), pp. 302-315, PMID 9862785 .
↑ Madras, BK; Fahey, MA; Goulet, M .; Lin, Z .; Bendor, J .; Goodrich, C .; Meltzer, PC; Elmaleh, DR; Livni, E; Bonab, AA; Fischman, AJ: Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. In: Journal of Pharmacology and Experimental Therapeutics. (November 2006; 319 (2)), pp. 570-585, PMID 16885433 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] PC Meltzer, AY Liang, BK Madras: The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. In: Journal of medicinal chemistry. Volume 37, Number 13, June 1994, pp. 2001-2010, PMID 8027983 .

[3] VC Campbell, TA Kopajtic, AH Newman, JL Katz: Assessment of the influence of histaminergic actions on cocaine-like effects of 3α-diphenylmethoxytropane analogs. In: The Journal of pharmacology and experimental therapeutics. Volume 315, Number 2, November 2005, pp. 631-640, doi : 10.1124 / jpet.105.090829 , PMID 16055673 .

[4] Katz, JL; Izenwasser, S .; Kline, RH; Allen, AC; Newman, AH: Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. In: Journal of Pharmacology and Experimental Therapeutics (Jan. 1999; 288 (1)), pp. 302-315, PMID 9862785 .

[5] Madras, BK; Fahey, MA; Goulet, M .; Lin, Z .; Bendor, J .; Goodrich, C .; Meltzer, PC; Elmaleh, DR; Livni, E; Bonab, AA; Fischman, AJ: Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. In: Journal of Pharmacology and Experimental Therapeutics. (November 2006; 319 (2)), pp. 570-585, PMID 16885433 .